Oncopeptides (ONCO) investor relations material

Strategic direction and growth

• Focus on commercializing Pepaxti in Europe, expanding indications, and leveraging global partnerships for growth.

• Achieved 91% year-over-year sales growth in Q1 2026, with strong momentum in European markets.

• Ongoing strategic expansion through new distribution agreements and multiple partnership discussions.

• Market exclusivity for Pepaxti in Europe until 2037, supporting long-term revenue potential.

• Targeting a SEK 1.5B European market and $8B+ global glioblastoma market.

Financial performance and projections

• European sales increased from SEK 13.3m in Q1 2025 to SEK 25.4m in Q1 2026.

• Full-year sales projected to more than double from SEK 31.6m in 2024 to SEK 71.1m in 2025.

• Approximately 800 patients treated since EMA approval in 2022, with growing adoption.

• Expected to establish a self-sustaining financial base by 2027.

Product and clinical development

• Pepaxti is fully approved in Europe for relapsed/refractory multiple myeloma (RRMM) after at least three prior therapies.

• Application underway to expand Pepaxti into third-line therapy, potentially doubling the addressable patient pool and treatment cycles.

• Real-world studies confirm efficacy and manageable safety profile of melflufen, including in heavily pretreated and renal-impaired patients.

• Inclusion in EHA/EMN guidelines with a 1B recommendation is driving awareness and adoption.